[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastricgastroesophageal-junction-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastricgastroesophageal-junction-adenocarcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,63,87,111,134,159,181,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100431255","phase-1-a-study-of-bms-986340-as-monotherapy-and-as-combination-therapy-in-participants-with-advanced-solid-tumors-100431255",false,"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","A Phase 1\u002F2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","Inclusion Criteria\n\n* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Radiographically documented progressive disease on or after the most recent therapy.\n* Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced\u002Fmetastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.\n* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.\n\nExclusion Criteria\n\n* Women who are pregnant or breastfeeding.\n* Primary central nervous system (CNS) malignancy.\n* Untreated CNS metastases.\n* Leptomeningeal metastases.\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.\n* Active, known, or suspected autoimmune disease.\n* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.\n* Prior organ or tissue allograft.\n* Uncontrolled or significant cardiovascular disease.\n* Major surgery within 4 weeks of study drug administration.\n* History of or with active interstitial lung disease or pulmonary fibrosis.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},1109,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.",[27,28,29,30,31,32,33,34,35,36,37],"Cervical Cancer","Gastric\u002FGastroesophageal Junction Adenocarcinoma","Microsatellite Stable Colorectal Cancer","Non-Small-Cell Lung Cancer","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Renal Cell","Urothelial Carcinoma","Pancreatic Adenocarcinoma","Melanoma","Ovarian Neoplasms","Triple Negative Breast Neoplasms",[39,27,40,41,42,28,43,29,44,45,30,46,47,31,32,33,34,35,36,37,48,49],"BMS-986340","CRC","First-in-human","GEJ","HNSCC","MSS CRC","Nivolumab","NSCLC","SCCHN","Docetaxel","Pumitamig","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2021-05-27",{"date":58,"type":20},"2031-08-31",{"name":60,"class":61},"Bristol-Myers Squibb","INDUSTRY",47,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100630121","phase-2-ibi343-in-combination-therapy-for-advanced-malignant-solid-tumors-100630121","NCT07483554","IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.","Inclusion criteria:\n\n1. Signed written informed consent, willing and able to comply with the protocol-specified visits and related procedures.\n2. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n3. Age ≥ 18 years, no gender restrictions.\n4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n5. Expected survival ≥ 12 weeks.\n6. Adequate bone marrow and organ function.\n7. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment.\n8. Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.\n\nExclusion criteria:\n\n1. Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.\n2. Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug.\n3. Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.\n4. Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.\n5. Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.\n6. Planning to receive other anti-tumor treatments during the period of treatment with the investigational drug.\n7. Received any live vaccine within 4 weeks prior to the first dose of the investigational drug or planning to receive any live vaccine during the study.\n8. Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.\n9. Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug.\n10. History of gastrointestinal perforation and\u002For fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.\n11. Presence of pyloric obstruction and\u002For persistent recurrent vomiting.\n12. Post-procedure of stent implantation in the digestive tract or trachea.\n13. Symptomatic central nervous system metastasis.\n14. Bone metastasis with risk of paraplegia.\n15. Interstitial lung disease requiring steroid treatment, or history of interstitial lung disease, non-infectious pneumonia, severe impairment of pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having these diseases during the screening period.\n16. Presence of uncontrolled disease.\n17. History of other primary malignant tumors.\n18. Known history of immunodeficiency.\n19. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n20. Previous treatment with topoisomerase inhibitor-based antibody-drug conjugates.\n21. For subjects receiving drug treatment, a history of allergy to the corresponding drug or formulation.\n22. For subjects receiving drug treatment, contraindications for the corresponding drug.\n23. For subjects receiving drug treatment, a history of permanent discontinuation of the corresponding drug due to related adverse reactions.\n24. Pregnant or lactating female subjects.\n25. Other conditions deemed unsuitable for participation in this study by the investigator.",{"count":71,"type":20},389,[24],"A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric\u002Fgastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.",[75,28,76],"CLDN18.2 Positive","Pancreatic Ductal Adenocarcinoma","2026-06-02",{"date":79,"type":54},"2026-06-03",{"date":81,"type":54},"2026-04-20",{"date":83,"type":20},"2028-03-31",{"name":85,"class":61},"Innovent Biologics (Suzhou) Co. Ltd.",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100614006","phase-2-zanidatamab-combined-with-chemotherapy-as-neoadjuvant-therapy-for-her2-high-expression-ggejc-100614006","NCT07273981","Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G\u002FGEJC","Phase II Clinical Study of Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for Locally Advanced HER2-high Expression (IHC3+\u002F2+FISH+) Gastric\u002FGastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Histologically\u002Fradiologically confirmed Stage II\u002FIII (cT1-2N+M0 or cT3-4aNanyM0) Siewert II\u002FIII GEJ\u002Fgastric adenocarcinoma.\n3. HER2-high (IHC 3+\u002F2+FISH+); HER2 2+ requires FISH (no time restriction).\n4. Age 18-75, any gender.\n5. ECOG 0-1, surgically eligible.\n6. Adequate organ function for abdominal surgery.\n7. Life expectancy ≥3 months.\n\nExclusion Criteria:\n\nExclusion Criteria\n\n1. Unresectable\u002Fmetastatic (Stage IV) disease.\n2. Prior systemic GC therapy.\n3. Other malignancies within 5 years (except those with \\>90% 5-year survival).\n4. Cardiopulmonary dysfunction.\n5. Major surgery within 4 weeks pre-study.\n6. Severe infection within 4 weeks.\n7. Prior chemo\u002Ftargeted therapy.\n8. Hypersensitivity to study drugs\u002Fexcipients\u002FmAbs.\n9. Factors impairing oral intake (e.g., ≥Grade 2 dysphagia\u002Fchronic diarrhea).\n10. Uncontrolled comorbidities affecting compliance\u002Foutcomes.\n11. Pregnancy\u002Flactation\u002Fplanned pregnancy.\n12. Immunosuppression (\\>10mg\u002Fday prednisone equivalent within 2 weeks).\n13. Active HBV (DNA ≥1×10³ copies\u002FmL or ≥200IU\u002FmL), HCV+, or HIV+.\n14. Other antitumor trials within 28 days.\n15. Other high-risk conditions (e.g., psychiatric disorders) per investigator.\n16. Refusal to sign consent.","75 Years",{"count":96,"type":20},30,[24],"HER2 overexpression is observed in approximately 20% of gastric cancers and gastroesophageal junction (GEJ) cancers, making it a validated target for anti-tumor therapy . In advanced-stage systemic therapy, trastuzumab combined with chemotherapy has demonstrated clinical benefits for HER2-positive gastric and GEJ cancers . However, the combination of trastuzumab and pertuzumab plus chemotherapy did not significantly improve overall survival (OS) compared to trastuzumab monotherapy in HER2-expressed gastric\u002FGEJ cancers .\n\nIn neoadjuvant therapy for early-stage or locally advanced gastric cancer, there is currently no standardized perioperative regimen for HER2-positive gastric or GEJ cancers, and effective treatment remains challenging .\n\nZanidatamab, a humanized bispecific IgG1-like antibody targeting HER2's ECD4 and ECD2 epitopes, exhibits unique enhanced functionality . Phase II studies (NCT03929666) showed that zanidatamab combined with chemotherapy as first-line therapy for HER2-positive advanced gastroesophageal adenocarcinoma (GEA) demonstrated superior survival benefits and durable responses compared to standard therapy (trastuzumab plus chemotherapy) . A Phase III study (HERIZON-GEA-01, NCT05152147) is now underway to further validate its efficacy when combined with chemotherapy ± tislelizumab versus trastuzumab-based chemotherapy .\n\nFor previously untreated stage II\u002FIII locally advanced gastroesophageal junction adenocarcinoma (cT1-2N+M0, cT3-4aNanyM0) with confirmed HER2 high expression (HER2 3+\u002F2+ FISH+), neoadjuvant zanidatamab combined with chemotherapy (FLOT\u002FSOX\u002FCAPOX) is being explored to evaluate safety and efficacy, potentially offering a new treatment option for HER2-positive GEJ cancers in perioperative settings .",[28],"NOT_YET_RECRUITING","2025-12-08",{"date":103,"type":54},"2025-12-10",{"date":105,"type":20},"2026-01-01",{"date":107,"type":20},"2029-07-31",{"name":109,"class":110},"Xijing Hospital","OTHER",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":86},"100610920","phase-2-a-phase-ii-clinical-study-evaluating-ssgj-706-in-combination-therapy-for-advanced-gastrointestinal-cancers-100610920","NCT07233850","A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","Inclusion Criteria:\n\n1. Volunteer to participate in this study, willing to follow all trial procedures, and sign the informed consent form (ICF).\n2. Age 18-75 years old, male or female.\n3. Has a life expectancy of at least 3 months\n4. ECOG score of 0-1.\n5. Locally advanced or metastatic tumors of the digestive system that cannot be curatively resected and cannot be treated with radical chemoradiotherapy, including gastric\u002Fgastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer.\n6. No prior systemic therapy in the locally advanced unresectable\u002Fmetastatic setting.\n7. Has at least 1 measurable lesion per RECIST version 1.1.\n8. Willing to provide a paraffin-embedded (FFPE) specimen or an unstained histopathological section (preferably a newly obtained tumor tissue sample).\n9. Has bone marrow, kidney, liver, blood and clotting test results required per protocol.\n10. Female subjects of childbearing age had a negative serum pregnancy test within 7 days before the first dose. Male and female subjects of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until at least 120 days after the last use of study drug and for at least 180 days after the last use of chemotherapy drugs or bevacizumab. During this period, women are not lactating, male subjects are not allowed to freeze or donate sperm, and female subjects are not allowed to donate eggs or retrieve eggs for personal use.\n\nExclusion Criteria:\n\n1. For gastric\u002Fgastroesophageal junction adenocarcinoma: HER2-positive (defined as IHC 3+, or IHC 2+ with ISH-positive).\n2. For colorectal cancer: Patients with known MSI-H or dMMR.\n3. Presence of brainstem, meningeal metastases, spinal cord metastases, or compression.\n4. Presence of active central nervous system (CNS) metastases; Subjects with previously treated brain metastases (such as surgery, radiotherapy) are allowed to enroll if they are clinically stable for at least four weeks after treatment (until the first dose of study drug) and corticosteroids are discontinued 3 days before the first dose of study drug; Subjects with untreated, asymptomatic brain metastases can be enrolled.\n5. Previous immunotherapy, including immune checkpoint inhibitors (e.g., PD-l\u002FL1 antibody, anti-CTLA-4 antibody, anti-TIGIT antibody, anti-LAG3 antibody, etc.), immune checkpoint agonists (e.g., ICOS, CD40, CD137, OX40 antibody, etc.), immune cell therapy and any other treatment targeting the mechanism of anti-tumor immune action.\n6. Adverse reactions caused by previous anti-tumor therapy need to be restored to grade ≤1 (as judged by NCI-CTCAE 5.0 criteria), except for alopecia and fatigue.\n7. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n8. Prior or current non-infectious pneumonitis\u002Finterstitial lung disease requiring systemic glucocorticoid therapy.\n9. History of severe bleeding tendency or coagulation dysfunction.\n10. Presence of gastrointestinal perforation and\u002For fistula, intra-abdominal abscess within 6 months before the first dose.\n11. Subjects with known active tuberculosis (TB).\n12. Known history of severe allergy to any component of the trial drug, or history of severe allergic reaction to chimeric or humanized antibodies.\n13. Other conditions that, in the opinion of the investigator, may increase study-related risks or interfere with the interpretation of study results.",{"count":118,"type":20},300,[24],"This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors. Its objective is to assess the safety, tolerability, and antitumor activity of SSGJ-706 in combination with standard treatment.",[28,122,123,124],"Metastatic Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Oesophageal Cancer","2025-11-14",{"date":127,"type":54},"2025-11-18",{"date":129,"type":20},"2025-11",{"date":131,"type":20},"2027-12",{"name":133,"class":61},"Shenyang Sunshine Pharmaceutical Co., LTD.",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100604354","phase-2-immunotherapy-combined-with-anti-angiogenic-therapy-and-chemotherapy-for-gastricgastroesophageal-junction-adenocarcinoma-100604354","NCT07148427","Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric\u002FGastroesophageal Junction Adenocarcinoma","A Single-arm, Phase II Clinical Study Protocol of Lparomlimab and Tuvonralimab in Combination With Regorafenib and Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Willing to participate in this study and has signed the informed consent form.\n* Age greater than 18 years, regardless of gender.\n* Histologically confirmed unresectable locally advanced or metastatic G\u002FGEJ adenocarcinoma.\n* No prior systemic treatment for unresectable locally advanced or metastatic G\u002FGEJ adenocarcinoma. Previous neoadjuvant and\u002For adjuvant therapy is acceptable, but all systemic treatments must have been completed at least 6 months prior to the diagnosis of unresectable or metastatic disease.\n* PD-L1 combined positive score (CPS) less than 1 as determined by tissue testing.\n* At least one measurable lesion according to RECIST 1.1 criteria.\n* ECOG performance status 0-1.\n* Life expectancy \\>3 months.\n* Adequate organ and marrow function:\n\nExclusion Criteria:\n\n* Known HER2-positive expression (immunohistochemistry \\[IHC\\] 3+ or 2+ with a fluorescence in situ hybridization HER2:CEP17 ratio ≥2).\n* Presence of other malignancies within 5 years prior to treatment, with the exception of adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, locally treated prostate cancer, and ductal carcinoma in situ (hormone therapy for non-metastatic prostate cancer or breast cancer is permitted).\n* Known central nervous system metastases and\u002For carcinomatous meningitis.\n* Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction.\n* Hypertension that cannot be controlled with antihypertensive medications (systolic blood pressure \\>140 mmHg, diastolic blood pressure \\>90 mmHg).\n* History of bleeding within 4 weeks prior to screening, with any bleeding event graded as ≥3 according to CTCAE 5.0.\n* Thrombotic events (arterial or venous) within 6 months prior to screening, such as cerebrovascular accident, deep vein thrombosis (excluding previously thrombosed veins deemed healed by the investigator), and pulmonary embolism.\n\n  8\\. History of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.\n\n  9\\. Patients who have previously received anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies at any time.",{"count":142,"type":20},40,[24],"A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric\u002Fgastroesophageal junction adenocarcinoma",[28],[147,148,149],"regorafenib","chemotherapy","Iparomlimab and Tuvonralimab","2025-08-28",{"date":152,"type":54},"2025-08-29",{"date":154,"type":20},"2025-09-20",{"date":156,"type":20},"2028-09",{"name":158,"class":110},"The First Affiliated Hospital with Nanjing Medical University",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":86},"100575587","phase-2-a-study-of-fruquintinib-plus-chemotherapy-for-postoperative-treatment-of-her2-negative-gastric-cancer-with-poor-trg-100575587","NCT06774222","A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG","A Phase II, Single-Arm, Single-Center Study of Fruquintinib Combined With Standard Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer Patients With Poor Tumor Regression Grade.","Inclusion Criteria:\n\n1. Fully understand the study and voluntarily sign the informed consent form;\n2. Age between 18 and 75 years;\n3. Histologically confirmed resectable or potentially resectable locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma;\n4. Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy;\n5. R0 resection after neoadjuvant chemotherapy;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n7. Life expectancy of at least 2 years;\n8. No prior anti-cancer treatment received;\n9. Good compliance and cooperation with follow-up.\n\nExclusion Criteria:\n\n1. Inability to comply with the study protocol or procedures;\n2. History of prior gastric cancer surgery;\n3. Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery;\n4. Distant metastasis to organs other than the liver, such as lung, brain, and bone;\n5. Known HER2-positive patients;\n6. Uncontrolled hypertension despite medication prior to enrollment;\n7. Poorly controlled diabetes despite medication prior to enrollment;\n8. Urine routine indicating proteinuria ≥2+, and a 24-hour urine protein quantification \\>1.0g;\n9. Presence of conditions requiring intervention such as bleeding, perforation, or obstruction prior to enrollment;\n10. Patients deemed ineligible for this study by the investigator.",{"count":167,"type":20},69,[24],"Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.",[28],"2025-01-13",{"date":173,"type":54},"2025-01-14",{"date":175,"type":54},"2023-09-12",{"date":177,"type":20},"2026-12-31",{"name":179,"class":180},"Henan Cancer Hospital","OTHER_GOV",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":4},"100574820","phase-2-tislelizumab-combined-with-sox-regimen-in-the-treatment-of-locally-advanced-gastric-cancergastroesophageal-junction-adenocarcinoma-100574820","NCT06764251","Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer\u002Fgastroesophageal Junction Adenocarcinoma","A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer\u002Fgastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Willing to participate in this study, able to sign the informed consent form, and with compliance;\n2. No gender restriction, aged ≥18 and ≤70 years (at the time of signing the informed consent form);\n3. ECO score of 0-1;\n4. Estimated survival ≥6 months;\n5. HER-2 negative;\n6. Central laboratory confirmed PD-L1 expression in the, with a combined positive score (CPS) ≥1;\n7. Histological and radiological assessment confirmed as advanced gastric cancer (GC) or gastroesal junction (GEJ) adenocarcinoma, with a clinical stage of cT3-T4aN M0;\n8. Pre-enrollment by the attending physician to determine eligibility for R0 resection with curative intent;\n9. Good cardiac function. Patients with underlying ischemic, valvular disease, or other severe heart disease should have a preoperative assessment by a cardiologist if there are clinical indications;\n10. No prior cytotoxic or targeted, no prior partial or complete esophagogastric tumor resection;\n11. Negative for hepatitis B surface antigen (HBsAg) and hepatitis core antibody (HBcAb). If HBsAg is positive or HBcAb is positive, then the hepatitis B virus deoxyribonucleic acidHBV-DNA) must be \\\u003C1000 copies\u002FmL or \\\u003C200 IU\u002FmL or \\\u003Cthe upper limit of normal (ULN) at research center to be eligible;\n12. Negative for hepatitis C virus (HCV) antibody;\n13. Normal major organ function, as defined by the criteria (within 14 days before the first dose, without transfusions, albumin, recombinant human thrombopoietin, or colony-stulating factor (CSF) treatment): Blood routine examination: Hemoglobin (Hb) ≥90g\u002FL; absolute neutrophil count (ANC ≥1.5×109\u002FL; platelets (PLT) ≥80×109\u002FL; Biochemical examination: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN liver metastasis); total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for Gilbert's syndrome); seruminine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60mL\u002Fmin; Coagulation function: Activated partialboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN; Dpler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%; Normal thyroid function, defined as thyroid-stimulating hormone (T) within the normal range. If baseline TSH is out of range, patients with total T3 (or FT3) and FT4 within the normal range also be included; Clinical judgment by the doctor that organ function is sufficient.\n14. Fertile subjects must use appropriate contraception during the study and for 20 days after the study ends, have a negative serum pregnancy test within 7 days before enrollment, and must not be breastfeeding\n\nExclusion Criteria:\n\n1. Have had or simultaneously have other active malignant tumors within 5 years. Cured localized tumors, as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast in situ, are eligible;\n2. Patients who are preparing for or have previously undergone organ or bone marrow transplantation;\n3. Have ≥2 grade myocardial ischem or myocardial infarction, arrhythmia (QTc ≥470ms), and ≥2 grade congestive heart failure (New York Heart AssociationNYHA\\] classification);\n4. Human immunodeficiency virus (HIV) infection;\n5. Have active pulmonary tuberculosis;\n6. Have a history or current presence interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe pulmonary dysfunction, etc., which may interfere with the detection and management of suspected drug-related pulmonary toxicity;\n7. Have known active or suspected autoimmune diseases, except those in a stable state at the time of enrollment (not requiring systemic immunospressive therapy);\n8. Have received live vaccine treatment within 28 days before the first dose; seasonal flu vaccines are not included;\n9. Have received or need receive systemic corticosteroids (\\> 10 mg\u002Fday prednisone equivalent dose) or other immunosuppressive drugs within 14 days before the dose or during the study. However, the following cases are allowed: patients with no active autoimmune diseases can use topical or inhaled corticosteroids, or hormone replacement therapy with a dose ≤ 10 mg\u002Fday prednisone equivalent dose;\n10. Have any active infection that requires systemic anti-infective within 14 days before the first dose; prophylactic antibiotic treatment (e.g., for urinary tract infections or chronic obstructive pulmonary disease) is not;\n11. Have previously received other antibodies\u002Fdrugs targeting immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.;\n12. Are currently receiving other clinical study treatments, or the time between the end of the previous clinical study treatment and the planned start of this study treatment is less than14 days;\n13. Have a known severe allergic history to any monoclonal antibody or excipients of the study drug;\n14. Have a history of psychiatric drug abuse or drug addiction; patients who have stopped drinking alcohol can be enrolled; According to the investigator's judgment, patients with serious concomitant that endanger the safety of the subjects or affect the completion of the study, or patients who are deemed unsuitable for enrollment for other reasons","70 Years",{"count":190,"type":20},20,[24],"This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma.",[28],"2025-01-01",{"date":196,"type":54},"2025-01-08",{"date":198,"type":20},"2024-12-30",{"date":83,"type":20},{"name":201,"class":110},"Liaoning Cancer Hospital & Institute",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":86},"100548029","phase-2-a-study-of-paclitaxel-combined-with-apatinib-and-adebrelimab-in-gastricgastroesophageal-junction-adenocarcinoma-100548029","NCT06415669","A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric\u002FGastroesophageal Junction Adenocarcinoma","A Study of Paclitaxel (Albumin-bound) Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy Progression","Inclusion Criteria:\n\n* 1\\) Age: 18 \\~ 75 years old, male and female;\n* 2\\) ECOG score: 0 or 1;\n* 3\\) Patients with unresectable locally advanced or metastatic gastric cancer\u002Fgastroesophageal junction adenocarcinoma confirmed by histopathology;\n* 4\\) Patients who have received at least first-line immunotherapy progression or intolerance in the past, and the number of previous systemic treatment lines does not exceed 2 lines; The best curative effect of frontline containing PD-1\u002FPD-L1 was CR, PR or SD;\n* 5\\) According to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located in the area of previous radiotherapy can also be selected as target lesions if progression is confirmed);\n* 6\\) The major organs function normally and meet the following criteria\n* a. In the past 14 days without the use of granulocyte colony-stimulating factor, the absolute value of neutrophil (ANC) ≥1.5x109 \u002FL;\n* b. Platelets ≥100×109 \u002FL in the past 14 days without blood transfusion;\n* c. Hemoglobin \\>90g\u002FL in the last 14 days without blood transfusion or use of erythropoietin;\n* d. Total bilirubin ≤1.5× upper limit of normal (ULN);\n* e. aspartate aminotransferase (AST), alanine aminotransferase (ALT) in\n\n  ≤2.5×ULN (ALT or AST ≤5×ULN for patients with liver metastasis);\n* f. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥40 ml\u002Fmin;\n* g. Good coagulation function, defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;\n* h. The myocardial enzyme profile is within the normal range (if the researchers comprehensively judge that the simple laboratory abnormality is not clinically significant, it is also allowed to be included);\n* 7\\) Expected survival ≥3 months;\n* 8\\) Women of reproductive age should agree to use contraceptives (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the study ends; Have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must be a non-lactating patient; Men should consent to patients who must use contraception during the study period and for 6 months after the end of the study period;\n* 9\\) Sign informed consent.\n\nExclusion Criteria:\n\n* 1\\) Patients who have previously received paclitaxel chemotherapy; Patients with neoadjuvant or adjuvant treatment with taxoid drugs and disease progression more than 6 months after the last chemotherapy were excluded;\n* 2\\) HER2-positive patients;\n* 3\\) Patients who are taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose \\>10mg\u002F day prednisone or other therapeutic hormone) and continue to use within 2 weeks before enrollment;\n* 4\\) Patients with severe liver and kidney insufficiency or heart insufficiency;\n* 5\\) have multiple factors that affect oral drugs (such as inability to swallow, gastrointestinal resection, chronic diarrhea, and intestinal obstruction);\n* 6\\) Patients with brain metastases accompanied by symptoms or symptom control for less than 3 months;\n* 7\\) Patients who are known to be allergic to any investigational drug or drug excipient;\n* 8\\) Pregnant or lactating female patients;\n* 9\\) Patients who underwent major surgical procedures (craniotomy, thoracotomy, or laparotomy) or had unhealed surgical wounds, ulcers, or fractures within 4 weeks prior to initial dosing, except for patients ≥2 weeks after surgery and patients with old fractures that the investigator determined could be treated with the study drug;\n* 10\\) Patients with moderate to severe ascites accompanied by clinical symptoms requiring repeated drainage; Patients with uncontrolled or clinical symptoms of pleural effusion or pericardial effusion;\n* 11\\) Patients with clinically significant electrolyte disorders;\n* 12\\) People with acute or chronic active hepatitis B or hepatitis C: hepatitis B virus (HBV) DNA \\> 2000IU\u002Fml or 104 copies \u002Fml; Hepatitis C virus (HCV) RNA \\> 103 copies \u002Fml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive patients;\n* 13\\) Patients with central nervous system metastasis, but with no clinical symptoms or accompanied by clinical symptoms after treatment, disease control and stable time ≥4 weeks can be enrolled; To meet the need for measurable lesions outside the central nervous system, hormone therapy should be discontinued 14 days before the first study of medication\n* 14\\) Any life-threatening bleeding event within the previous 3 months, including patients requiring transfusion therapy, surgery or local therapy, and ongoing medication;\n* 15\\) Patients with a history of arteriovenous thromboembolism events, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other severe thromboembolism within the past 6 months. The exception is implantable intravenous infusion port or catheter-derived thrombosis, or superficial venous thrombosis, which is stable after conventional anticoagulant therapy. Allow patients to prophylactically use small doses of low molecular weight heparin (e.g., enoxaparin 40 mg\u002F day);\n* 16\\) Uncontrolled hypertension, systolic blood pressure \\> 160 MMHG or diastolic blood pressure \\> 100mmHg after optimal medical treatment, hypertensive crisis or hypertensive encephalopathy history;\n* 17\\) Symptomatic congestive heart failure (New York Heart Association Grade II-IV). Symptomatic or poorly controlled arrhythmia. Patients with a history of congenital long QT syndrome or a QTc \\> 500ms (calculated using the Fridericia method) corrected at screening;\n* 18\\) For patients who received radiation therapy more than 4 weeks before the first treatment, all of the following conditions must be met to be enrolled: there is no current toxic reaction related to radiation therapy, no need to take glucocorticoids, and radiation pneumonia, radiation hepatitis, and radiation enteritis are excluded;\n* 19\\) Patients with previous or current pulmonary diseases such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, and severe impairment of lung function;\n* 20\\) Human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive), known syphilis infection;\n* 21\\) Patients with unhealed wounds, fractures, gastric and duodenal ulcers, persistent positive stool occultiblood, ulcerative colitis, or other conditions that researchers have determined may cause gastrointestinal bleeding or perforation;\n* 22\\) All adverse events during the screening period have not returned to baseline or ≤ Grade 1 (NCI-CTCAE V5.0) (except for alopecia, or peripheral sensory neuropathy, which can be grade 2);\n* 23\\) Patients with severe infections that are active or poorly controlled clinically. Patients with severe infections in the 4 weeks prior to initial dosing, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia;\n* 24\\) Use of immunosuppressive drugs within 4 weeks prior to initial administration, excluding nasal, inhaled, or other routes of topical corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10mg\u002F day of prednisone or equivalent doses of other corticosteroids); To allow temporary use of glucocorticoids for the treatment of breathing difficulties in diseases such as asthma and chronic obstructive pulmonary disease;\n* 25\\) Patients who received live attenuated vaccine within 4 weeks prior to initial administration or who planned to receive live attenuated vaccine during the study period;\n* 26\\) Patients who received major surgical treatment or significant traumatic injury 4 weeks prior to initial dosing\n* 27\\) Patients who received traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose;\n* 28\\) Patients with a history of gastrointestinal perforation or abscess within 6 months prior to enrollment;\n* 29\\) Received treatment in other clinical trials within 4 weeks prior to initial dosing;\n* 30\\) Patients whose urine routine indicated urinary protein ≥2+, or 24-hour urinary protein quantity \\>1.0g;\n* 31\\) The presence of any active autoimmune disease or history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis); Patients with asthma requiring medical intervention with bronchodilators were not included); However, the following patients were admitted: vitiligo, psoriasis, alopecia, well-controlled type I diabetes without systemic therapy, hypothyroidism with normal thyroid function treated by replacement therapy;\n* 32\\) Other acute or chronic medical conditions, psychiatric disorders, or abnormalities in laboratory test values that may contribute to these results: increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and, in the investigator's judgment, classify patients as ineligible to participate in the study;\n* 33\\) Other situations deemed unsuitable for inclusion by the researcher.",{"count":96,"type":20},[24],"To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric\u002Fgastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.",[28],[214,215,216,217,218],"paclitaxel","apatinib","adebrelimab","adenocarcinoma of the gastroesophageal junction","gastric carcinoma","2024-05-26",{"date":221,"type":54},"2024-05-29",{"date":223,"type":54},"2024-05-19",{"date":225,"type":20},"2027-05-19",{"name":227,"class":110},"The First Affiliated Hospital of Xiamen University"]